B cells as biofactories for therapeutic protein delivery for rare diseases
Seattle, WA
Joined March 2016
- Tweets89
- Following93
- Followers189
- Likes90
Pinned Tweet
Thanks @WIRED @emilylmullin for speaking with our CEO Sean Ainsworth about the first engineered B cell therapy dosed in human trials: 🧬🧬🧬
wired.com/story/b-cells-gene…
We’re excited to announce our presentation at @WORLDSymposia 2024 Conference, held in San Diego, February 4-9. WORLDSymposium is the largest international gathering of lysosomal disease researchers.
Read the full release:
businesswire.com/news/home/2…
.@DDWJournal covers our recent first patient dosed using the world’s first engineered B cell therapy. 🧬🧬🧬
ddw-online.com/worlds-first-…
Immusoft Corporation retweeted
A trial by Seattle-based Immusoft, a biotech company, said it is the first to genetically engineer B cells and test them in a patient, Wired reported Dec. 15. bit.ly/3TtmJH2
Immusoft Corporation retweeted
CIRM is proud to support @immusoft's groundbreaking B cell therapy trial for MPS I and other diseases.
"Our goal is always to move the most promising research forward as fast as we can,” said Dr. Abla Creasey, VP of Therapeutics Development at CIRM.
wired.com/story/b-cells-gene…
Thanks @Inside_PM for covering our first patient dosed news!
insideprecisionmedicine.com/…
Immusoft Corporation retweeted
@emilylmullin, from @WIRED, writes: "@immusoft announced that its scientists have genetically programmed a patient’s B cells and put them back in his body in an effort to treat disease. It’s the first time engineered B cells have been tested in a person." bit.ly/3RKOj1q
.@FierceBiotech covers our first patient dosed for the world’s first engineered B cell therapy. 🧬🧬🧬
fiercebiotech.com/biotech/fi…
Immusoft Corporation retweeted
Incredibly proud to announce that Immusoft has dosed the first ever patient with an engineered b cell, and with none of the preconditioning or immunosuppression needed for gene modified stem cells or gene therapy. That's huge.
wired.com/story/b-cells-gene…
Immusoft Corporation retweeted
Immusoft Begins Clinical Trial of Autologous B-Cell Therapy in Mucopolysaccharidosis Type I. ISP-001, which Immusoft developed using its Immune System Programming platform, aims to reprogram patients' B cells so they keep producing alpha-L-iduronidase. ow.ly/pCGK1055NEQ
Immusoft Corporation retweeted
Engineering B-cells:
First in human
trial in patient with mucopolysaccharidosis type I
Ex vivo B-cell gene engineering to produce missing enzyme by @immusoft
wired.com/story/b-cells-gene…
Immusoft Corporation retweeted
The Westcott family first invested in @immusoft in 2013 when the idea of genetically engineering B-cells (antibody) was just that…an idea. Ten years later, they have dosed their first patient. One day this technology could change millions of lives. We are proud to have played a small part.
wired.com/story/b-cells-gene…
CC: @VCBrags
#biotech #bcells #VentureCapital
Immusoft Corporation retweeted
Immusoft Administers the First Engineered B Cell in a Human Clinical Trial dlvr.it/T09svn
Immusoft Corporation retweeted
Great companies, in great company! Honored for Aurion to share BioFuture Stage with @endpts @leileiwuu, Sean Ainsworth @Immusoft, Christine Silverstein @ExcisionBio, Liz Wood @JuraBio to talk about the future of cell and gene therapy: how it will transform patient care.
Immusoft Corporation retweeted
At this year's @ASGCTherapy annual meeting, engineered B cells are shining 🤩
Beautiful abstracts from @PaulaUSC Matthew Porteus, Jennifer Adair, @JustinTaylorLab , @HPKiem , Richard James and David Rawlings, @immusoft and @bebiopharma
Immusoft Corporation retweeted
M&A #news
~@immusoft acquires exclusive, worldwide rights to @UMNews's #IP for #genome edited primary B Cells
~#BiminiHealthTech acquires exclusive license to #accellular dermal matrix product portfolio
~@Mindstrong sells #tech assets to @SonderMind
ALT Image Source: https://bhbusiness.com/2023/03/22/sondermind-acquires-mindstrongs-tech-as-part-of-final-wind-down/
Excited to announce we’ve acquired the exclusive worldwide rights to IP for #genomeediting technology for primary B cells. 🧬🧬🧬
Read the full release:
businesswire.com/news/home/2…
Immusoft Corporation retweeted
Genome-editing of primary B cells is becoming increasingly important in this space. It’s exciting to be a scientific advisor to Immusoft, the leader in engineered B cells. @eqxfund @immusoft #proudinvestor businesswire.com/news/home/2…
Immusoft Corporation retweeted
@immusoft secures $ 8M from @CIRMnews to advance the engineered B cell clinical program.
The funds will help to initiate a clinical trial for ISP-001, an engineered autologous B-cell therapy intended for the treatment of mucopolysaccharidosis type I.
bit.ly/3KleiJf
